Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

• Percentage of patients with at least one visit response of CR or PR using revised response criteria (Cheson et al 2007), who have a duration of response of at least 24 weeks. [ Time Frame: From week 8 after randomization until disease progression or discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: No ]
• Progression Free Survival as defined by the time from randomization until the date of objective relapse/progression or death. [ Time Frame: From week 8 after randomization until disease progression or discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: No ]
  By any cause in the absence of relapse or progression regardless of whether the patient withdraws from randomized.
• Duration of Response as defined by the time from the date of first documented response (CR or PR) until the date of documented relapse/progression or death [ Time Frame: From week 8 after randomization until disease progression or discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: No ]
• Percentage of patients with serious adverse events and adverse events. [ Time Frame: From randomization until discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: Yes ]
• Individual plasma clearance (Cl) [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing ] [ Designated as safety issue: No ]
• Initial volume (VL) [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing. ] [ Designated as safety issue: No ]
• Peripheral volume (VT) [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing. ] [ Designated as safety issue: No ]
• Distributional clearance. [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing. ] [ Designated as safety issue: No ]

• Percentage of patients with at least one visit response of CR or PR using revised response criteria (Cheson et al, 2007), who have a duration of reponse of at least 24 weeks. [ Time Frame: From week 8 after randomization until disease progression or discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: No ]
• Progression Free Survival as defined by the time from randomization until the date of objective relapse/progression or death. [ Time Frame: From week 8 after randomization until disease progression or discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: No ]
  By any cause in the absence of relapse or progression regardless of whether the patient withdraws from randomized.
• Duration of Response as defined by the time from the date of first documented response (CR or PR) until the date of documented relapse/progression or death [ Time Frame: From week 8 after randomization until disease progression or discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: No ]
• Percentage of patients with serious adverse events and adverse events. [ Time Frame: From randomization until discontinuation from study (expected duration of treatment: approximately 6 months) ] [ Designated as safety issue: Yes ]
• Individual plasma clearance (Cl) [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing ] [ Designated as safety issue: No ]
• Initial volume (VL) [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing. ] [ Designated as safety issue: No ]
• Peripheral volume (VT) [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing. ] [ Designated as safety issue: No ]
• Distributional clearance. [ Time Frame: Before dosing, and at 1, 2, 4 and 8 hours after dosing. ] [ Designated as safety issue: No ]

This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)

Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Inclusion Criteria:

• Aged at least 18 years of age.
• Patients with relapsed or refractory diffuse large B-cell lymphoma who have previously received R-CHOP (or equivalent) chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue.
• Measurable disease as defined by Cheson et al 2007 criteria.
• One fresh pre-treatment excisional or core needle biopsy from suitable and accessible site.
• World Health Organization (WHO) performance status 0 to 1.

Exclusion Criteria:

• Treatment with nitrosurea, mitomycin C, investigational agents or study drugs w/in28 days of first dose of study treatment, any other chemotherapy, immunotherapy or anticancer agents w/in 3 weeks of first dose of study treatment, previous fostamatinib.
• With the exception of alopecia, any unresolved toxicities from prior therapy or surgery greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.
• Uncontrolled hypertension (defined as >140mmHg systolic and/or > 90 mmHG diastolic at baseline with or without antihypertensive therapy.
• Evidence of tuberculosis (TB).
• Inadequate boen marrow reserve.